A detailed history of Raymond James & Associates transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 273,591 shares of HALO stock, worth $12.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
273,591
Previous 146,261 87.06%
Holding current value
$12.9 Million
Previous $7.66 Million 104.39%
% of portfolio
0.01%
Previous 0.01%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$51.3 - $64.42 $6.53 Million - $8.2 Million
127,330 Added 87.06%
273,591 $15.7 Million
Q2 2024

Jul 19, 2024

BUY
$37.81 - $52.4 $1.89 Million - $2.62 Million
49,923 Added 51.82%
146,261 $7.66 Million
Q1 2024

Apr 22, 2024

BUY
$33.68 - $41.95 $864,700 - $1.08 Million
25,674 Added 36.33%
96,338 $3.92 Million
Q4 2023

Jan 16, 2024

SELL
$33.32 - $42.1 $221,811 - $280,259
-6,657 Reduced 8.61%
70,664 $2.61 Million
Q3 2023

Oct 24, 2023

SELL
$36.46 - $44.03 $21,256 - $25,669
-583 Reduced 0.75%
77,321 $2.95 Million
Q2 2023

Jul 25, 2023

SELL
$30.28 - $38.74 $880,330 - $1.13 Million
-29,073 Reduced 27.18%
77,904 $2.81 Million
Q1 2023

Apr 14, 2023

BUY
$32.86 - $55.7 $84,680 - $143,538
2,577 Added 2.47%
106,977 $4.09 Million
Q4 2022

Feb 08, 2023

BUY
$40.06 - $59.44 $1.18 Million - $1.76 Million
29,546 Added 39.47%
104,400 $5.94 Million
Q3 2022

Oct 25, 2022

BUY
$38.53 - $51.78 $1.28 Million - $1.72 Million
33,149 Added 79.48%
74,854 $2.96 Million
Q2 2022

Aug 12, 2022

BUY
$37.35 - $48.3 $310,154 - $401,083
8,304 Added 24.86%
41,705 $1.84 Million
Q1 2022

May 11, 2022

SELL
$31.97 - $41.06 $568,842 - $730,580
-17,793 Reduced 34.76%
33,401 $1.33 Million
Q4 2021

Feb 08, 2022

BUY
$31.82 - $40.75 $510,679 - $653,996
16,049 Added 45.67%
51,194 $2.06 Million
Q3 2021

Nov 02, 2021

SELL
$38.47 - $46.42 $25,467 - $30,730
-662 Reduced 1.85%
35,145 $1.43 Million
Q2 2021

Aug 11, 2021

BUY
$38.84 - $51.31 $217,387 - $287,182
5,597 Added 18.53%
35,807 $1.63 Million
Q1 2021

May 14, 2021

SELL
$39.51 - $51.45 $708,809 - $923,013
-17,940 Reduced 37.26%
30,210 $1.26 Million
Q4 2020

Feb 12, 2021

BUY
$25.81 - $43.62 $453,868 - $767,057
17,585 Added 57.53%
48,150 $2.06 Million
Q3 2020

Nov 04, 2020

BUY
$25.74 - $29.63 $203,912 - $234,728
7,922 Added 34.99%
30,565 $803,000
Q2 2020

Jul 28, 2020

BUY
$16.25 - $26.81 $10,481 - $17,292
645 Added 2.93%
22,643 $607,000
Q1 2020

Apr 21, 2020

SELL
$13.9 - $21.83 $25,228 - $39,621
-1,815 Reduced 7.62%
21,998 $396,000
Q4 2019

Feb 12, 2020

BUY
$14.93 - $19.53 $1,254 - $1,640
84 Added 0.35%
23,813 $422,000
Q3 2019

Nov 07, 2019

BUY
$15.2 - $17.69 $360,680 - $419,766
23,729 New
23,729 $368,000
Q4 2018

Feb 11, 2019

SELL
$13.33 - $18.66 $199,790 - $279,676
-14,988 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$16.68 - $18.41 $30,641 - $33,819
1,837 Added 13.97%
14,988 $272,000
Q2 2018

Aug 14, 2018

BUY
$16.87 - $20.3 $221,857 - $266,965
13,151 New
13,151 $222,000
Q1 2018

May 14, 2018

SELL
$17.06 - $21.2 $182,286 - $226,522
-10,685 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$16.75 - $20.8 $178,973 - $222,248
10,685
10,685 $216,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.57B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.